Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Global Rybrevant Bispecific Antibody Market to 2028 - Featuring Affimed Therapeutics, Amgen and Eli Lilly Among Others -

November 5, 2021 GMT

DUBLIN--(BUSINESS WIRE)--Nov 5, 2021--

The “Rybrevant Bispecific Antibody Patent, Sales & Clinical Trials Outlook 2028” report has been added to’s offering.

The approval of drug Rybrevant in early 2021 is thought to revolutionize the paradigm treatment of EFGR mutated non-small cell lung cancer. It is expected that in short span of time, the drug will constitute a major share in the lung cancer therapeutics owing to the single product approval targeting EFGR mutations. It is analyzed that the market will witness high compound annual growth rates to surpass US$ 4 Billion by 2028. Apart from this, the favorable reimbursement policies including Janssen Care Path will also boost the uptake of drug in the market. Furthermore, the subsequent years will see approval of Rybrevant in different regions, which will further boost the growth of market.


Rybrevant Bispecific Antibody Patent, Sales & Clinical Trials Outlook 2028 Report Analysis & Data Highlights:

  • Rybrevant Patent Insight
  • Rybrevant Dosage & Price
  • Rybrevant Sales Forecast 2028: > USD 4 Billion
  • Rybrevant Role in NSCLC & Other Cancer Therapies
  • Rybrevant Structure & Pharmacokinetics Properties
  • Rybrevant Ongoing Clinical Trials: > 5 Clinical Studies
  • Rybrevant Reimbursement Scenario

The development of bispecific antibodies represents one of the most promising successes in cancer targeted therapy research and development. Bispecific antibodies are dual targeting modalities which can simultaneously combine two epitopes. Their novel dual binding efficacy opens up a wide range of applications application which can be exploited in redirecting T-cells, blocking two different signaling pathways, dual targeting of different disease mediators and delivering payloads to targeted cells. Owing to their enhance specificity, they are considered as ideal therapeutic molecule for the management of multifactorial cancers.


Recently in 2021, a novel bispecific antibody Rybrevant (Amivantamab) was granted approval by US FDA. Rybrevant is an EGF and MET directed bispecific antibody, developed by Janssen Pharmaceutical which is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EFGR) exon 20 insertion mutations. Clinical trials have demonstrated that the novel drug has shown enhanced efficacy in comparison to previously approved MET and EFGR inhibitors. As of now, the drug has only gained approval in US. However, it has filed regulatory submissions in other regions including Europe, China, Japan, and other regions.

Apart from non-small cell lung cancer, the drug is also being evaluated in other cancers including adenoid cystic carcinoma (ACC), stomach cancer, esophageal cancers, and other solid tumors. In addition to this, investigators are also validating the role of drug in combination with carboplatin, lazertrinib, osimertinib, and others which aim to enhance the efficacy of the drug. As per our analysis, the future will see dominance of combinational therapy which is mainly due to its increased efficiency and enhance survival outcomes.

Scientists are constantly exploring the sector of bispecific antibodies. Their multifactorial approach in the management of diseases and their ability to pass through the blood brain barrier is gaining the interest of various researchers. Extensive efforts by research institutions and pharmaceutical sector are boosting the global bispecific antibody market. The major key players in the market are Amgen, Genmab, Eli Lilly, NovImmune, Sanofi, Roche, AstraZeneca, and several others. These have developed robust pipeline of bispecific antibodies which will compete with already approved bispecifics in market.

Key Topics Covered:

1. Rybrevant (Amivantamab-vmjw): Third Approved Bispecific Antibody 2021

1.1 Overview

1.2 Approval & Patent Insight

2. Rybrevant Dosage & Price Analysis

3. Rybrevant - Structure, Description & Pharmacokinetics

4. Rybrevant Mechanism of Action

4.1 General Mechanism of Bispecific Antibodies

4.2 Rybrevant

5. Rybrevant Role in NSCLC

6. Rybrevant Role in Other Cancers

7. Rybrevant - Supplementary Information

7.1 Adverse Drug Reactions

7.2 Application in Specific Population

8. Rybrevant Market Analysis

8.1 Current Market Scenario

8.2 Future Market Opportunity

9. Rybrevant Sales Forecast

10. Rybrevant Reimbursement Policy

11. Rybrevant Clinical Trials Insight

11.1 By Phase

11.2 By Development Status

11.3 By Region

12. Ongoing Research & Development

13. Companies Developing Similar Bispecific Antibodies

13.1 Ablynx

13.2 Adimab

13.3 Affimed Therapeutics

13.4 Amgen

13.5 AstraZeneca (MedImmune)

13.6 Chugai Pharmaceutical

13.7 Eli Lilly

13.8 EMD Serono

13.9 Emergent BioSolutions

13.10 Genentech

13.11 Genmab

13.12 Immunomedics

13.13 Jounce Therapeutics

13.14 MacroGenics

13.15 Merus

13.16 Neovii Biotech

13.17 NovImmune

13.18 OncoMed Pharmaceuticals

13.19 Pieris

13.20 Regeneron Pharmaceuticals

13.21 Roche

13.22 Sanofi

For more information about this report visit

View source version on


Laura Wood, Senior Press Manager

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900



SOURCE: Research and Markets

Copyright Business Wire 2021.

PUB: 11/05/2021 06:14 AM/DISC: 11/05/2021 06:14 AM